A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment.

Trial Profile

A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2014

At a glance

  • Drugs Safinamide (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Newron Sweden AB
  • Most Recent Events

    • 20 Jun 2012 Actual patient number is 103 according to ClinicalTrials.gov.
    • 20 Jun 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
    • 20 Jun 2012 Status changed from active, no longer recruiting to completed as reported by Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top